Drug Database
HY

hydrocodone + ibuprofen (Ibudone)

✓ Approved

Kowa · OPRM1 · 小分子

什么是 hydrocodone + ibuprofen?

hydrocodone + ibuprofen 是一种小分子,由Kowa研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Ibudone
公司Kowa
药物类别小分子
分子靶点OPRM1, PTGS1, PTGS2
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

hydrocodone + ibuprofen 作用于 3 个分子靶点:

OPRM1opioid receptor mu 1 (MOR, MOP)
PTGS1prostaglandin-endoperoxide synthase 1 (PGHS-1, PTGHS)
PTGS2prostaglandin-endoperoxide synthase 2 (COX-2, COX2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

hydrocodone + ibuprofen 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersAbdominal pain✓ Approved

相关研究文献

PubMedInternational journal of biological macromolecules2026-11-18

An ibuprofen-loaded ionic-covalent dual-network hydrogel for enhanced wound healing.

Ban Xiaoyan X, Cui Yating Y, Wang Chen C, Wang Zhikai Z et al.

Multifunctional hydrogel dressings with mechanical robustness, exudate absorption, antibacterial and anti-inflammatory capacities are greatly needed for complex wound treatment. Herein, an ibuprofen-laden ionic-covalent dual-network hydrogel AP/SA/CaCl2@IBP was fabricated via covalent PAAm/PEGDA crosslinking and ionic SA-Ca2+ coordination, in which Ca2+ ions organize the alginate chains into egg-box junctions. The hydrogel shows favorable mechanical properties: tensile strength of ~32 kPa and elongation at break near 100%. Its pH-dependent swelling ratio between 100% and 200% allows efficient wound exudate uptake. It achieves antibacterial inhibition greater than 92% against E.coli and over 99% against S.aureus, with DPPH radical scavenging of approximately 43% and ABTS radical scavenging of approximately 34%. The actual IBP loading reached 1.980 ± 0.035 mg/gel, and in vitro assays showed pH-dependent IBP release over 72 h. Biological tests indicate favorable cytocompatibility, hemolysis ratios below 5%, and improved scratch closure. Immunofluorescence analysis showed changes in macrophage-associated inflammatory marker expression. In a rat full-thickness skin wound model, the IBP-loaded hydrogel exhibited approximately 79% wound closure on day 7, accompanied by increased collagen deposition and stronger early CD31-positive staining than the blank group. Owing to integrated multifunctions, AP/SA/CaCl2@IBP serves as a promising candidate for advanced wound repair dressings.

PMID 43051328
阅读全文 →
PubMedThe journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians2026-11-17

Retraction statement: Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial.

PMID 43045157
阅读全文 →
PubMedFrontiers in medicine2026-11-17

Vanishing bile duct syndrome reports and recorded fatal outcomes in FAERS: a disproportionality analysis.

Yin Yi Y, Zhang Guiju G

Vanishing bile duct syndrome (VBDS) is a rare but life-threatening condition characterized by progressive destruction of intrahepatic bile ducts, often leading to cirrhosis and death. Large-scale pharmacovigilance studies systematically investigating VBDS reports, particularly those with reported fatal outcomes, remain scarce. We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2004 Q1-2025 Q4). VBDS reports were identified using the MedDRA preferred term "Vanishing bile duct syndrome" (Code 10054753). We applied four algorithms-reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayesian geometric mean (EBGM). A positive signal required meeting criteria for all four methods simultaneously. For drugs meeting signal criteria, we further performed a two-dimensional cross-analysis by intersecting drugs with the highest total report counts and those with the highest death counts, to identify drugs appearing in both top-10 rankings. After deduplication, 19,588,161 unique adverse event reports were available, among which 997 reports coded as VBDS were identified. A death outcome was recorded in 193 reports (19.36%); this proportion reflects FAERS reporting patterns and should not be interpreted as VBDS-attributable mortality or a clinical case-fatality estimate. Disproportionality analysis identified 48 drugs meeting all four signal criteria. Notably, only carbamazepine explicitly mentioned VBDS in its FDA label, and merely 18 of the 48 drugs included the broader term "cholestasis". Through cross-analysis of total report counts and reported death counts, six drugs appeared in both top-10 ranking lists: ibuprofen, ciprofloxacin, azithromycin, sulfamethoxazole-trimethoprim, avacopan, and celecoxib. This large-scale pharmacovigilance analysis of FAERS suggests the mention of VBDS among FDA product labels differs across drugs generating post-marketing safety signals, and that this difference warrants further regulatory and clinical evaluation. Six agents (ibuprofen, ciprofloxacin, azithromycin, sulfamethoxazole-trimethoprim, avacopan, celecoxib) appeared in both top-10 ranking lists for total VBDS reports and reported death counts. Because these rankings are based on descriptive absolute FAERS report counts, these agents warrant further clinical and pharmacovigilance evaluation, particularly in patients with pre-existing risk factors for DILI. These findings may support pharmacovigilance surveillance and hypothesis generation, but should be interpreted as reporting associations rather than the evidence of causality.

PMID 43041357
阅读全文 →
PubMedWater environment research : a research publication of the Water Environment Federation2026-11-17

Potential Effects of Nonantibiotic Emerging Contaminant Degradation on Antibiotic Resistance Genes in Effluent-Impacted Hyporheic Zones.

Xie Yue Y, Jin Zepeng Z, Wang Dianqi D, Su Ting T et al.

Hyporheic zones (HZs) are hotspots of antibiotic resistance genes (ARGs) in rivers. Nonantibiotic emerging contaminants (ECs) discharged from wastewater treatment plants (WWTPs) can exert selective pressure on microbial communities and contribute to ARGs dissemination. However, the role of microbial ECs degradation in ARGs dissemination through co-selection remains poorly understood. In this study, HZs sediment samples were collected from two rivers dominated by WWTPs effluent and analyzed using metagenomic sequencing to investigate the co-selection effects of ECs on ARGs. A custom database of ECs degradation genes (ECDGs) was constructed by integrating information from EnviPath, KEGG Xenobiotics modules, and Eawag-BBD, totally covering 187 contaminants. Using this database, ECDGs associated with 78 ECs were identified, with genes associated with industrial pollutants predominating. After samples affected by a WWTP shutdown were excluded, ARGs and ECDGs were significantly correlated across both rivers and seasons (p < 0.05). Network analysis identified 11 potential ECDGs hosts that were also associated with ARGs, with Phenylobacterium being the most abundant genus. Co-localization analysis revealed 3824 contigs harboring both ARGs and ECDGs, of which 2395 were identified as plasmid-like sequences. These findings suggest widespread potential for co-resistance involving ARGs and ECDGs. In addition, a total of 4250 open reading frames (ORFs) were identified as having cross-resistance potential. Analysis of reconstructed metagenome-assembled genomes recovered complete pathways for kanamycin resistance and ibuprofen degradation that shared an ORF. These site-specific results provide genomic evidence that ECs discharged from WWTPs could promote ARGs dissemination through co-selection in HZs.

PMID 43042740
阅读全文 →
PubMedTranslational sports medicine2026-11-17

The Convergent Renal Insult: Why Endurance Athletes' Self-Medication With Nonsteroidal Anti-Inflammatory Drugs Requires a Sport-Specific Risk Model-A Narrative Review From Pharmaceutical and Sport-Science Perspectives.

Will Andreas A

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely consumed pharmacological agents in endurance sport, with reported prevalence of 14.8%-88% and consumption dominated by prophylactic rather than therapeutic intent despite three meta-analyses demonstrating no ergogenic effect. This use is sustained by a decision architecture in which pain is reframed as a controllable barrier to performance, prophylactic dosing is normalized within the training group, and renal risk is systematically underestimated: Among IRONMAN triathletes, only 27% were aware of it. This narrative review reframes the safety problem around the kidney. During prolonged high-intensity exercise, three stressors converge: sympathetic renal vasoconstriction, progressive dehydration activating the renin-angiotensin-aldosterone system, and NSAID-mediated prostaglandin inhibition, removing the compensatory vasodilatory safety net. This sport-specific convergent renal insult differs structurally from the clinical triple whammy because the first two stressors are intrinsic to the activity itself. The clinical manifestation appears intensity- and duration-dependent: Ibuprofen increased acute kidney injury rates from 34% to 52% during an 80-km ultramarathon stage (NNH 5.5; not statistically significant) but did not amplify biomarker responses during one hour of moderate running. Whether repeated transient insults accumulate into chronic kidney disease, as established for occupational heat-stress nephropathy and for hospital-documented AKI, remains the central unanswered question for habitual athletic NSAID users. Among the guideline documents reviewed, none currently addresses habitual over-the-counter NSAID use under exercise-induced renal stress in healthy athletes. The epidemiology and decision architecture of repeated exposure, the renal evidence base, the cumulative-exposure question, and the gap in current guidance together define future research needs for endurance-sport analgesic pharmacovigilance.

PMID 43041990
阅读全文 →
PubMedCurrent pain and headache reports2026-11-16

Suzetrigine Use in the Perioperative Period: A Narrative Review.

Passman Justin N JN, Fernandes Glen G, Gritsenko Karina K

Effective perioperative pain management is central to anesthesia and enhanced recovery after surgery protocols. Opioids remain the mainstay for moderate-to-severe postoperative pain, but their adverse effects, including CNS depression and dependency, have driven the search for non-opioid alternatives. Suzetrigine, the first selective NaV1.8 inhibitor approved for moderate-to-severe acute pain in adults, offers a novel mechanism by selectively blocking nociceptive signaling in peripheral sensory neurons and is the first new class of analgesics in decades. Phase III trials in patients undergoing abdominoplasty and bunionectomy demonstrated that suzetrigine reduced postoperative pain versus placebo with a favorable safety profile. Efficacy was generally comparable to hydrocodone/acetaminophen, and its opioid-sparing profile makes it an attractive component of multimodal perioperative analgesia. This review summarizes suzetrigine's pharmacology and emerging role in perioperative pain management, emphasizing its integration into multimodal analgesic pathways, opioid-sparing potential, and directions for future study.

PMID 43035587
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多hydrocodone + ibuprofen